ホーム / コンテンツ / Conferences / 2nd Annual Gene Therapy Immunogenicity

2nd Annual Gene Therapy Immunogenicity

2nd Annual Gene Therapy Immunogenicity
Speaker(s)
Immunogenicity Prediction and Dose Optimization using Proven In Silico Modeling & Simulation
Piet van der Graaf | Sr. Vice President
FDA’s risk based guidance for managing IG is focusing on the use of modeling & simulation for proteins, vaccines and new modalities, This immunogenicity modeling technology is being applied to address the unmet needs emerging from advanced therapies, specifically gene therapy, A case study demonstrating the use of this approach for dose optimization for gene therapy will be shared
トップに戻る
Powered by Translations.com GlobalLink OneLink Software